We have observed
19 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 20, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ANTIBODIES THAT ARE CROSS-REACTIVE FOR MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AND D-DOPACHROME TAUTOMERASE (D-DT)
USE OF C-FMS ANTAGONISTS
COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD
COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A PURINE ANALOG
ANTAGONISTS OF IL17C FOR THE TREATMENT OF INFLAMMATORY DISORDERS
Generation and profiling of fully human HuCAL GOLD(RTM)-derived therapeutic antibodies specific for human CD38
USE OF LYSOZYME AS A TAG
COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
COMBINATIONS AND USES THEREOF
RADIOLABELLED ANTIBODY AND USES THEREOF
Anti-CD38 human antibodies and uses therefor
ANTIBODIES TARGETING M-CSF
ANTIBODIES TARGETING SPECIFICALLY HUMAN CXCR2
GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38
TREATMENT FOR MULTIPLE MYELOMA (MM)
CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA